Lipidomic profiling of human serum enables detection of pancreatic cancer

Denise Wolrab, Robert Jirásko, Eva Cífková, Marcus Höring, Ding Mei, Michaela Chocholoušková, Ondřej Peterka, Jakub Idkowiak, Tereza Hrnčiarová, Ladislav Kuchař, Robert Ahrends, Radana Brumarová, David Friedecký, Gabriel Vivo-Truyols, Pavel Škrha, Jan Škrha, Radek Kučera, Bohuslav Melichar, Gerhard Liebisch, Ralph Burkhardt, Markus R. Wenk, Amaury Cazenave-Gassiot, Petr Karásek, Ivo Novotný, Kristína Greplová, Roman Hrstka and Michal Holčapek ()
Additional contact information
Denise Wolrab: University of Pardubice
Robert Jirásko: University of Pardubice
Eva Cífková: University of Pardubice
Marcus Höring: University Hospital of Regensburg
Ding Mei: National University of Singapore
Michaela Chocholoušková: University of Pardubice
Ondřej Peterka: University of Pardubice
Jakub Idkowiak: University of Pardubice
Tereza Hrnčiarová: University of Pardubice
Ladislav Kuchař: Charles University and General University Hospital in Prague
Robert Ahrends: University of Vienna
Radana Brumarová: Institute of Molecular and Translational Medicine
David Friedecký: Institute of Molecular and Translational Medicine
Gabriel Vivo-Truyols: Tecnometrix
Pavel Škrha: Charles University
Jan Škrha: Charles University
Radek Kučera: University Hospital in Pilsen
Bohuslav Melichar: Palacký University and University Hospital
Gerhard Liebisch: University Hospital of Regensburg
Ralph Burkhardt: University Hospital of Regensburg
Markus R. Wenk: National University of Singapore
Amaury Cazenave-Gassiot: National University of Singapore
Petr Karásek: Masaryk Memorial Cancer Institute
Ivo Novotný: Masaryk Memorial Cancer Institute
Kristína Greplová: Masaryk University
Roman Hrstka: Masaryk Memorial Cancer Institute
Michal Holčapek: University of Pardubice

Nature Communications, 2022, vol. 13, issue 1, 1-16

Abstract: Abstract Pancreatic cancer has the worst prognosis among all cancers. Cancer screening of body fluids may improve the survival time prognosis of patients, who are often diagnosed too late at an incurable stage. Several studies report the dysregulation of lipid metabolism in tumor cells, suggesting that changes in the blood lipidome may accompany tumor growth. Here we show that the comprehensive mass spectrometric determination of a wide range of serum lipids reveals statistically significant differences between pancreatic cancer patients and healthy controls, as visualized by multivariate data analysis. Three phases of biomarker discovery research (discovery, qualification, and verification) are applied for 830 samples in total, which shows the dysregulation of some very long chain sphingomyelins, ceramides, and (lyso)phosphatidylcholines. The sensitivity and specificity to diagnose pancreatic cancer are over 90%, which outperforms CA 19-9, especially at an early stage, and is comparable to established diagnostic imaging methods. Furthermore, selected lipid species indicate a potential as prognostic biomarkers.

Date: 2022
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-27765-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-021-27765-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-27765-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().